Erasca, Inc. (ERAS): Price and Financial Metrics


Erasca, Inc. (ERAS): $5.61

0.07 (+1.26%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ERAS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ERAS Stock Price Chart Interactive Chart >

Price chart for ERAS

ERAS Price/Volume Stats

Current price $5.61 52-week high $24.47
Prev. close $5.54 52-week low $5.23
Day low $5.36 Volume 409,573
Day high $5.75 Avg. volume 716,835
50-day MA $7.68 Dividend yield N/A
200-day MA $14.10 Market Cap 683.62M

Erasca, Inc. (ERAS) Company Bio


Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of NSCLC, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. The company was incorporated in 2018 and is headquartered in San Diego, California.


ERAS Latest News Stream


Event/Time News Detail
Loading, please wait...

ERAS Latest Social Stream


Loading social stream, please wait...

View Full ERAS Social Stream

Latest ERAS News From Around the Web

Below are the latest news stories about Erasca Inc that investors may wish to consider to help them evaluate ERAS as an investment opportunity.

Is a Surprise Coming for Erasca (ERAS) This Earnings Season?

Erasca (ERAS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Yahoo | February 8, 2022

Erasca to Present at the Guggenheim Healthcare Talks 2022 Oncology Day

SAN DIEGO, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Guggenheim Healthcare Talks 2022 Oncology Day. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a virtual fireside chat beginning a

Yahoo | February 3, 2022

Edmonds Duncan Registered Investment Advisors, LLC Buys VanEck Vectors Semiconductor ETF, ...

Investment company Edmonds Duncan Registered Investment Advisors, LLC (Current Portfolio) buys VanEck Vectors Semiconductor ETF, Erasca Inc, Concentrix Corp, Tenet Healthcare Corp, Palo Alto Networks Inc, sells WisdomTree Japan Hedged Equity Fund, PayPal Holdings Inc, Alphabet Inc, Boeing Co, Walmart Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Edmonds Duncan Registered Investment Advisors, LLC.

Yahoo | January 27, 2022

Erasca Strengthens Leadership Team with Two Key Executive Appointments

Lisa Tesvich-Bonora appointed as Chief People Officer Robert Shoemaker promoted to Senior Vice President of Research SAN DIEGO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Lisa Tesvich-Bonora as Chief People Officer and the promotion of Robert Shoemaker to Senior Vice Presi

Yahoo | January 18, 2022

Erasca to Present at the 40th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 40th annual J.P. Morgan Healthcare Conference. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, will present an overview of the company and pipeline at 3:45 pm Eastern Time on Monday, January 10, 2022. Dr. Li

Yahoo | January 4, 2022

Read More 'ERAS' Stories Here

ERAS Price Returns

1-mo -30.22%
3-mo -53.83%
6-mo -63.43%
1-year N/A
3-year N/A
5-year N/A
YTD -63.99%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.192 seconds.